Better Context → Better Decisions
Context counts in life sciences. The FENIX analyst team is tirelessly using its experience to put you in a position to succeed. Below, our readers without corporate access will find a wealth of contextualized life science insight ready to be purchased in the FENIX Marketplace. If our content sharing limitations are inconvenient for you, reach out to Brady for unlimited corporate, institutional, or individual access.
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 24 | 2025Novo Wins with Amycretin Ph1/2 Data; Another Obesity IPO; Allurion Gastric Balloon+GLP-1RA TrialPurchase Blast
$599
Posted in: Insulin Delivery, Topics Jan 23 | 2025Beta Bionics Set to IPO with $635M ValuationPurchase Blast
$599
Posted in: ESPR, Glucose Monitoring, Other, Topics Jan 22 | 2025Abbott Q4 ‘24 Earnings; Esperion KOL EventPurchase Blast
$599
Posted in: Other, Topics Jan 21 | 2025FDA Accepts Plozasiran NDA for FCS; Cytokinetics Opens Ph2 AMBER-HFpEF Trial EnrollmentPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 17 | 2025Sema on Medicare Negotiation List; STEP UP Topline Results; Long-Term Cagrisema Trial; EMA Reviewing Sema for NAION RiskPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jan 16 | 2025JPM 2025 Day 4: SKYE, ESPR, TRNS, IVAPurchase Blast$599
Posted in: Allogeneic, Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jan 15 | 2025JPM 2025 Day 3: PODD, MDGL, BMEA, IONS, SANA; Novo Wins PRV; Mounajro DTC; Lexaria Oral Liraglutide; Wisp Sublingual SemaPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Glucagon, Other, SGLT2i, Topics Jan 14 | 2025JPM 2025 Day 2: LLY, AZN, SNY, NVS, BAY, AKRO, SRRK, SDZ, MRK, TDOC, VTRS; Dario Partners for GLP-1RA Solution ExpansionPurchase Blast$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jan 13 | 2025JPM 2025 Day 1: DXCM, AMGN, VKTX, PFE, ZEAL, MDT, REGN, VTX, ALNY, CYTK; Metsera Files for IPO; Fractyl REVEAL-1 Data; Ro Zepbound DTC; 89bio 2025 OutlookPurchase Blast
$599
Posted in: GLP-1RA, Other, Topics Jan 10 | 2025Diamyd Type C Meeting Updates; Kardigan Launches as CV Company; Regor Topline Ph2a Results for Oral GLP-1RAPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 10 | 2025Zepbound OSA Label and Website AnalysisPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 10 | 2025FENIX Analysis: How Will Amgen Price MariTide in Obesity?Purchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Jan 09 | 2025Lilly/Thrive Partnership for LillyDirect; Verdiva Lauches as Obesity Company; Senseonics Business UpdatesPurchase Blast
$599
Posted in: Bolus Insulin, Dual/triple agonist, GLP-1RA, Other, Topics Jan 08 | 2025FDA Draft AOM Guidance; Novo/Valo Expand Partnership; Viking Initiates Oral VK2735 Ph2 Trial; Glooko/Hedia Integration; Sana Islet Cell Therapy T1DM Success; Found Expands to Dissolvable Oral SemaglutidePurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Insulin Delivery, Other, Topics Jan 07 | 2025Novo/Variant Partnership; Metsera Ph2a GLP-RA Data; Tandem/UVA Partnership; Biomea Icovamenib/Semaglutide Preclinical Data; Diamyd Publication; CeQur Financing RoundPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, Topics Jan 06 | 2025OFA Responds to Novo’s Petition on Semaglutide Compounding; PreEvnt Announces New Non-Invasive Glucose Monitor; Novo Holdings and Lilly Invest in Orbis Series A FinancingPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Jan 03 | 2025Lilly Requests to Join Compounding Lawsuit; 2026 Medicare/Medicaid Obesity Proposal; Novo Petitions FDA For CompoundingPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Glucose Monitoring, Other, SGLT2i, Topics Jan 03 | 2025Holiday Hangover: FDA Approves Zepbound for OSA; NICE Finalizes Tirzepatide Guidelines; Abbott and Dexcom Reach Agreement; Arrowhead Ph1/2a ARO-INHBE Trial in Obesity; AZ Initiates Ph2 MASH Trial; Zealand Petrelintide Commentary; Generic Liraglutide Approvals; Lexicon Receives CRL for ZynquistaPurchase Blast
$599
Posted in: Other, Topics Dec 20 | 2024Dexcom Participates in Oura Funding; Galectin Misses MASH Endpoint in Ph2b/3 TrialPurchase Blast
$599
Posted in: Dual/triple agonist, GLP-1RA, Other, Topics Dec 20 | 2024Cagrisema Misses Weight Loss TargetPurchase BlastGet the Latest Analysis
Stay informed and aligned with frequent updates to keep a pulse on the industry.
If you already have an account, please log in. If you have any questions or would like to subscribe to our services, please contact Brady.
